430 related articles for article (PubMed ID: 28142119)
1. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice.
Jeong HS; Kim KH; Lee IS; Park JY; Kim Y; Kim KS; Jang HJ
Biomed Pharmacother; 2017 Apr; 88():625-634. PubMed ID: 28142119
[TBL] [Abstract][Full Text] [Related]
2. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease.
Yang Y; Chen J; Gao Q; Shan X; Wang J; Lv Z
Toxicology; 2020 Dec; 445():152599. PubMed ID: 32976958
[TBL] [Abstract][Full Text] [Related]
3. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
4. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.
Xia H; Zhu X; Zhang X; Jiang H; Li B; Wang Z; Li D; Jin Y
Biomed Pharmacother; 2019 Oct; 118():109287. PubMed ID: 31401392
[TBL] [Abstract][Full Text] [Related]
5. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
6. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis.
Chen X; Li L; Liu X; Luo R; Liao G; Li L; Liu J; Cheng J; Lu Y; Chen Y
Life Sci; 2018 Jun; 203():291-304. PubMed ID: 29709653
[TBL] [Abstract][Full Text] [Related]
7. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
8. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
9.
Liu YL; Lin LC; Tung YT; Ho ST; Chen YL; Lin CC; Wu JH
Int J Med Sci; 2017; 14(9):862-870. PubMed ID: 28824323
[TBL] [Abstract][Full Text] [Related]
10. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
11. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis.
Marin V; Gazzin S; Gambaro SE; Dal Ben M; Calligaris S; Anese M; Raseni A; Avellini C; Giraudi PJ; Tiribelli C; Rosso N
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28895929
[TBL] [Abstract][Full Text] [Related]
12. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
[TBL] [Abstract][Full Text] [Related]
13. Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice.
Zhang L; Yang B; Yu B
Biol Pharm Bull; 2015; 38(7):1005-11. PubMed ID: 25972092
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effect of herb formula KIOM2012H against nonalcoholic fatty liver disease.
Park H; Hwang YH; Kim DG; Jeon J; Ma JY
Nutrients; 2015 Apr; 7(4):2440-55. PubMed ID: 25849950
[TBL] [Abstract][Full Text] [Related]
15. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
17. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.
Rao Y; Lu YT; Li C; Song QQ; Xu YH; Xu Z; Hu YT; Yu H; Gao L; Gu LQ; Ye JM; Huang ZS
Br J Pharmacol; 2019 Aug; 176(16):2877-2893. PubMed ID: 31113010
[TBL] [Abstract][Full Text] [Related]
18. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
19. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
[TBL] [Abstract][Full Text] [Related]
20. Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice.
Hong SA; Jung IR; Choi SE; Hwang Y; Lee SJ; Son Y; Heo YJ; Cui R; Han SJ; Kim HJ; Lee KW; Kang Y
Sci Rep; 2019 Nov; 9(1):17839. PubMed ID: 31780766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
